• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Servier (Group)

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of €4.2 billion in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) into research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, cancer and metabolism, immune-inflammatory and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. *

 

	Start	1954-01-01 established
	Industry	pharmaceutical
	Industry 2	cancer drug
	Street	50 rue Carnot
	City	92284 Suresnes Cedex
	Tel	+33-1-5572-6000
		Address record changed: 2014-11-26
Basic data	Employees	H: 10,001 to 50,00 (2019-06-05)
	Currency	EUR
	Annual sales	4,200,000,000 (turnover, consolidated (2018) 2018-12-31)
		* Document for �About Section�: Yposkesi. (6/5/19). "Press Release: Servier Appoints Yposkesi for Lentiviral Vector GMP-Manufacturing in CAR-T Cell Development Technology". Suresnes & Corbeil-Essonnes.
		Record changed: 2019-06-10

Advertisement

More documents for Servier (Group)

• [1] GeNeuro S.A.. (9/18/18). "Press Release: GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier". Paris & Geneva....
• [2] GeNeuro S.A.. (12/21/17). "Press Release: GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study". Geneva....
• [3] Servier. (11/2/17). "Press Release: Servier Germany to Co-promote Novartis’ Blockbuster Entresto"....
• [4] Servier. (2/14/17). "Press Release: Servier and GAIA Extend Their Partnership to Provide Patients around the World with Deprexis, an Internet-based Cognitive Behavioral Therapy for Depression". Suresnes & Hamburg....
• [5] Pieris Pharmaceuticals, Inc.. (1/5/17). "Press Release: Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance". Boston, MA & Suresnes....
• [6] Servier. (12/18/15). "Press Release: GeNeuro Announces the Launch of Phase IIb Proof-of-Concept Study with GNbAC1 in Multiple Sclerosis and Servier Equity Investment". Geneva & Suresnes....
• [7] Servier. (12/7/15). "Press Release: Servier Announces Expansion of Collaboration for the Development and Commercialization of Anticancer Drug Candidates Targeting Apoptosis". Suresnes....
• [8] Servier. (6/15/15). "Press Release: Taiho Pharmaceutical Co., Ltd. and Servier Enter into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe". Tokyo....
• [9] GeNeuro S.A.. (12/2/14). "Press Release: GeNeuro and Servier Sign Partnership to Develop First Medicine Addressing a Causal Factor of Multiple Sclerosis". Geneva & Suresnes....
• [10] Boehringer Ingelheim. (8/3/12). "Press Release: Boehringer Ingelheim Biopharmaceuticals Announces Manufacturing Agreement with Servier". Ingelheim....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.